NEWS
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
Unicycive Therapeutics (Nasdaq: UNCY) has been granted U.S. Patent No. 12,036,211 by the USPTO for UNI-494, ensuring intellectual property protection until 2040. The patent covers a method of treating acute kidney injury or contrast-induced nephropathy using the UNI-494 compound, a novel nicotinamide ester derivative and selective ATP-sensitive mitochondrial potassium channel activator.
UNI-494 is currently in a Phase 1 clinical trial and has received Orphan Drug Designation for Delayed Graft Function, a form of acute kidney injury. This patent is a important component of Unicycive's strategy to become a leader in developing drugs targeting kidney disease.
UNI-494 is currently in a Phase 1 clinical trial and has received Orphan Drug Designation for Delayed Graft Function, a form of acute kidney injury. This patent is a important component of Unicycive's strategy to become a leader in developing drugs targeting kidney disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment